REVB
REVELATION BIOSCIENCES, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Aug 14 ▲ Short interest falls 25.7% to 15.4K
- Aug 31 ▲ Short interest falls 96.2% to 582
- Sep 15 ▲ Short interest falls 56.0% to 256
- Sep 30 ▼ Short interest jumps 517.6% to 1.6K
- Oct 15 ▼ Short interest jumps 317.8% to 6.6K
- Oct 19 Trading halt: Trading Halt: REVB, T1 (News Pending)
- Oct 19 Trading halt: Trading Halt: REVB, T3 (News and Resumption Times)
- Oct 20 Trading halt: Halt Resumed: REVB, trading resumed after LUDP (Volatility…
- Oct 20 Trading halt: Trading Halt: REVB, LUDP (Volatility Trading Pause)
- Oct 20 Trading halt: Halt Resumed: REVB, trading resumed after T3 (News and Res…
- Oct 30 ▼ Short interest jumps 93.7% to 12.8K
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q2 2026: 0 added (0 new), 1 trimmed or exited.
- Short sellersBUILDING
Short interest +93.7% to 12.8K shares. 1.0 days to cover, ≈1.9% of shares.
- TrendDOWNTREND
25% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | $17.7K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Rolke James Chief Executive Officer Aug 17, 2026 | AWARD | 208,076 sh |
ROPER JESS Director Aug 17, 2026 | AWARD | 32,011 sh |
Chawla Lakhmir S Director Aug 17, 2026 | AWARD | 32,011 sh |
Zygmont Chester Stanley III Chief Financial Officer Aug 17, 2026 | AWARD | 208,073 sh |
Zygmont Chester Stanley III Chief Financial Officer Aug 17, 2026 | GIFT | 208,073 sh |
CARVER JENNIFER Director Aug 17, 2026 | AWARD | 32,011 sh |
Rolke James Chief Executive Officer Apr 30, 2026 | TAX W/H | $11.4K |
Zygmont Chester Stanley III Chief Financial Officer Apr 30, 2026 | TAX W/H | $14.6K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | None | None | No data | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026| Oct 20, 2026 | Volatility Pause | Resumed |
| Oct 19, 2026 | Resumption Scheduled | Resumed |
SecBot reports
4 filings · 0 bullish · 1 bearish · 3 neutral- NEUTRAL 8-KNov 13, 2026
Revelation Biosciences filed an 8-K to disclose its intention to use social media channels (X…
Monitor the identified social media channels and the company's website for future material disclosures, as the company may use these channels for first disclosure of material information.
- BEARISH 8-KNov 5, 2026
Revelation Biosciences reported Q3 2026 net loss of $3.3M ($5.92 per share) vs $1.9M ($49.51 per…
Monitor initiation and enrollment of the Gemini AKI study, as it is the nearest catalyst. Cash runway into Q2 2027 suggests a potential financing need before mid-2027 if burn rate continues.
- NEUTRAL 8-KAug 19, 2026
Revelation Biosciences granted restricted stock awards to CEO James Rolke (208,076 shares) and CFO…
This is a routine equity grant with no immediate trading signal. The vesting milestones are set far above current market cap ($4M vs $30M+), making near-term dilution unlikely. Monitor for any…
- NEUTRAL 8-KJun 24, 2026
Revelation Biosciences filed an 8-K covering: (1) amended CEO/CFO employment agreements with…
The reverse split authorization (up to 1:250) signals potential Nasdaq compliance efforts, monitor for announcement of specific ratio and timing. The enhanced change-in-control severance provisions…
All REVB filing & press-release reports (4)
- 8-K reportNov 13, 2026
- 8-K reportNov 5, 2026
- 8-K reportAug 19, 2026
- 8-K reportJun 24, 2026